The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of EGFR tyrosine kinase inhibitors on skeletal-related events in EGFR mutation-positive non-small cell lung cancer patients with bone metastases.
Tatsuya Yoshida
No relevant relationships to disclose
Kiyotaka Yoh
No relevant relationships to disclose
Koichi Goto
No relevant relationships to disclose
Shigeki Umemura
No relevant relationships to disclose
Seiji Niho
No relevant relationships to disclose
Hironobu Ohmatsu
No relevant relationships to disclose
Kanji Nagai
No relevant relationships to disclose
Yuichiro Ohe
No relevant relationships to disclose